WuXi AppTec, a China-based global company that provides R&D and manufacturing services for the pharmaceutical and life science industries, announced on Thursday that its Nantong site (Phase I) has been recognised as the Popular Choice Winner in the 'Factory & Warehouse' category at the 2025 Architizer A+Awards.
According to WuXi AppTec, this award recognises its commitment to creating innovative, human-centric workplaces that empower employees and support customers in delivering transformative therapies for patients.
The Architizer A+Awards aim to celebrate groundbreaking designs that redefine functionality and aesthetics. Competing against thousands of entries from over 80 countries, the award organiser said that WuXi AppTec's Nantong site stood out for its visionary design concept of 'technological-humanistic symbiosis'.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA